Rare diseases as a strategic driver of Europe’s biotech leadership
For decades, Europe has been losing ground in the global competition for life sciences investment, research, and development. The Biotech
Read more
Industry
Europe’s preparedness will only be as strong as its vaccine and biotech base
Europe cannot afford to rediscover preparedness only when the next crisis arrives. COVID-19 exposed deep vulnerabilities in health security, manufacturing
Read more
How the Biotech Act should reinforce the public trust in Europe’s health systems
Today, European patients wait on average more than 578 days to access new medicines after approval from the European Medicines
Read more
The Biotech Act can help Europe compete again in life sciences but on its own cannot deliver the change that Europe urgently requires
Europe has enormous strengths in science, manufacturing and its industrial base, but struggles to translate this into investment, clinical trials
Read more
From breakthrough to manufacturing: Europe’s biotech sector must build what it invents
The future of European biotech may be taking shape in a former factory in Delft. A familiar building to me.
Read more
Biotechnology, medical countermeasures and preparedness: DG HERA’s role in Europe’s health sovereignty
Six years after the COVID-19 pandemic fundamentally changed our perception of health security, one lesson remains undeniable: preparedness is not
Read more
Scaling Europe’s biotech industry: from research excellence to industrial leadership
For the past decades, Europe has been treating biotechnology primarily as a health policy issue. That was a mistake. Biotech
Read more
Securing Europe’s Health Sovereignty: From Innovation to Outcomes
Health sovereignty today is not defined by physical control alone: stockpiles, warehouses or emergency reserves. Those still matter, but the
Read more